Literature DB >> 11470559

Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia.

A Marutle1, X Zhang, J Court, M Piggott, M Johnson, R Perry, E Perry, A Nordberg.   

Abstract

The laminar cortical distribution of the [125I]alpha-bungarotoxin, [3H]cytisine and [3H]epibatidine nicotinic acetylcholine receptor ligands was investigated by quantitative autoradiography in autopsy tissue from the cingulate, orbitofrontal and temporal cortices of control and schizophrenia subjects matched for age and smoking history. Different laminar binding patterns were observed for the various nicotinic ligands both in schizophrenic and control brains. [125I]alpha-Bungarotoxin binding was distributed homogeneously across all cortical layers in all three brain regions, with highest binding densities in the cingulate cortex. [3H]Cytisine and [3H]epibatidine binding varied across the cortical ribbon, with high binding in layers I, III, V and VI, within the three cortical regions. A significantly reduced [125I] alpha-bungarotoxin binding (-54%) was observed in the cingulate cortex of schizophrenia subjects, in comparison with normal individuals who smoked tobacco. In the same brain region also a significantly higher [3H]cytisine binding (48-77%) was observed in nearly all layers, except for layer I of the schizophrenia subjects, when compared to normal individuals with a history of tobacco use. No significant changes in [3H]epibatidine binding was observed within the individual cortical layers between control subjects and patients with schizophrenia, but when calculated as a whole region (i.e. measurements performed across the whole cortical ribbon), the temporal cortex showed a significant increase in [3H]epibatidine binding in schizophrenia subjects compared to control subjects. The results suggest opposite changes of the alpha4beta2 and alpha7 nicotinic receptor subtypes in the cingulate cortex of patients with schizophrenia which might reflect involvement of two different nicotinic receptor mechanisms in schizophrenia brain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11470559     DOI: 10.1016/s0891-0618(01)00117-x

Source DB:  PubMed          Journal:  J Chem Neuroanat        ISSN: 0891-0618            Impact factor:   3.052


  70 in total

Review 1.  The genetics of sensory gating deficits in schizophrenia.

Authors:  Robert Freedman; Ann Olincy; Randall G Ross; Merilyne C Waldo; Karen E Stevens; Lawrence E Adler; Sherry Leonard
Journal:  Curr Psychiatry Rep       Date:  2003-06       Impact factor: 5.285

Review 2.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

3.  Transcriptional repression of the α7 nicotinic acetylcholine receptor subunit gene (CHRNA7) by activating protein-2α (AP-2α).

Authors:  Jessica Finlay-Schultz; Andrew Canastar; Margaret Short; Mohamed El Gazzar; Christina Coughlan; Sherry Leonard
Journal:  J Biol Chem       Date:  2011-10-06       Impact factor: 5.157

Review 4.  Mouse models for studying genetic influences on factors determining smoking cessation success in humans.

Authors:  F Scott Hall; Athina Markou; Edward D Levin; George R Uhl
Journal:  Ann N Y Acad Sci       Date:  2012-02       Impact factor: 5.691

Review 5.  Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models.

Authors:  L Lyon; L M Saksida; T J Bussey
Journal:  Psychopharmacology (Berl)       Date:  2011-11-10       Impact factor: 4.530

6.  Spatial and intracellular relationships between the alpha7 nicotinic acetylcholine receptor and the vesicular acetylcholine transporter in the prefrontal cortex of rat and mouse.

Authors:  A M Duffy; P Zhou; T A Milner; V M Pickel
Journal:  Neuroscience       Date:  2009-04-15       Impact factor: 3.590

7.  Effects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.

Authors:  L Elliot Hong; Gunvant K Thaker; Robert P McMahon; Ann Summerfelt; Jill Rachbeisel; Rebecca L Fuller; Ikwunga Wonodi; Robert W Buchanan; Carol Myers; Stephen J Heishman; Jeff Yang; Adrienne Nye
Journal:  Arch Gen Psychiatry       Date:  2011-08-01

8.  A 2-base pair deletion polymorphism in the partial duplication of the alpha7 nicotinic acetylcholine gene (CHRFAM7A) on chromosome 15q14 is associated with schizophrenia.

Authors:  Melissa L Sinkus; Michael J Lee; Judith Gault; Judith Logel; Margaret Short; Robert Freedman; Susan L Christian; Jennifer Lyon; Sherry Leonard
Journal:  Brain Res       Date:  2009-07-23       Impact factor: 3.252

Review 9.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

10.  Association of the 5'-upstream regulatory region of the alpha7 nicotinic acetylcholine receptor subunit gene (CHRNA7) with schizophrenia.

Authors:  Sarah H Stephens; Judith Logel; Amanda Barton; Alexis Franks; Jessica Schultz; Margaret Short; Jane Dickenson; Benjamin James; Tasha E Fingerlin; Brandie Wagner; Colin Hodgkinson; Sharon Graw; Randal G Ross; Robert Freedman; Sherry Leonard
Journal:  Schizophr Res       Date:  2009-01-31       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.